Robert Vonderheide

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Telomerase-based immunotherapy of cancer
    Erica L Carpenter
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRBII III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Expert Opin Biol Ther 6:1031-9. 2006
  2. ncbi request reprint Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 7:3343-8. 2001
  3. ncbi request reprint Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, Abramson Cancer Center, Division of Hematology Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Oncol 25:876-83. 2007
  4. pmc Prospects and challenges of building a cancer vaccine targeting telomerase
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRBII III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Biochimie 90:173-80. 2008
  5. ncbi request reprint Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Discov Med 7:103-8. 2007
  6. ncbi request reprint Prospect of targeting the CD40 pathway for cancer therapy
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Clin Cancer Res 13:1083-8. 2007
  7. ncbi request reprint A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center and the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Immunol Res 27:341-56. 2003
  8. ncbi request reprint Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 61:8366-70. 2001
  9. ncbi request reprint RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy
    Christina M Coughlin
    Division of Hematology and Oncology, Children s Hospital of Philadelphia, and Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 19104, USA
    Blood 103:2046-54. 2004
  10. ncbi request reprint Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application
    Michael S von Bergwelt-Baildon
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 99:3319-25. 2002

Research Grants

  1. TELOMERASE AS A WIDELY EXPRESSED TUMOR ANTIGEN
    Robert Vonderheide; Fiscal Year: 2004
  2. Immunoregulation and immunotherapy of breast cancer
    Robert Vonderheide; Fiscal Year: 2005
  3. Immunoregulation and immunotherapy of breast cancer
    Robert Vonderheide; Fiscal Year: 2006
  4. Immunoregulation and immunotherapy of breast cancer
    Robert Vonderheide; Fiscal Year: 2007
  5. Immunoregulation and immunotherapy of breast cancer
    Robert Vonderheide; Fiscal Year: 2009
  6. Immunoregulation and immunotherapy of breast cancer
    Robert H Vonderheide; Fiscal Year: 2010

Collaborators

Detail Information

Publications40

  1. ncbi request reprint Telomerase-based immunotherapy of cancer
    Erica L Carpenter
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRBII III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Expert Opin Biol Ther 6:1031-9. 2006
    ..Immunotherapy induces functional, antitumour T cells in patients in the absence of clinical toxicity. The opportunity for vaccinating individuals as an immunoprevention strategy can also be envisioned for hTERT-based therapies...
  2. ncbi request reprint Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 7:3343-8. 2001
    ..The applicability of hTERT as a potential target for anticancer immunotherapy would be widened by the identification of epitopes restricted to other common HLA alleles, such as HLA-A3 antigen...
  3. ncbi request reprint Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, Abramson Cancer Center, Division of Hematology Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Oncol 25:876-83. 2007
    ..CD40 is also expressed by solid tumors, but its engagement results in apoptosis. CP-870,893, a fully human and selective CD40 agonist monoclonal antibody (mAb), was tested for safety in a phase I dose-escalation study...
  4. pmc Prospects and challenges of building a cancer vaccine targeting telomerase
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRBII III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Biochimie 90:173-80. 2008
    ....
  5. ncbi request reprint Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Discov Med 7:103-8. 2007
    ....
  6. ncbi request reprint Prospect of targeting the CD40 pathway for cancer therapy
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Clin Cancer Res 13:1083-8. 2007
    ....
  7. ncbi request reprint A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center and the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Immunol Res 27:341-56. 2003
    ..Phase I trials translating these discoveries to novel active and passive T cell therapies have been initiated, with an eye toward combining these strategies once safety is established...
  8. ncbi request reprint Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 61:8366-70. 2001
    ..These findings support clinical efforts to target the hTERT as a tumor antigen with broad therapeutic potential...
  9. ncbi request reprint RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy
    Christina M Coughlin
    Division of Hematology and Oncology, Children s Hospital of Philadelphia, and Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 19104, USA
    Blood 103:2046-54. 2004
    ..These findings support a novel platform for tumor-specific vaccine or adoptive immunotherapies in pediatric malignancies...
  10. ncbi request reprint Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application
    Michael S von Bergwelt-Baildon
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 99:3319-25. 2002
    ..Therefore, they are an excellent source of professional APCs for immune assessment, antigen discovery, and antigen-specific immunotherapy...
  11. ncbi request reprint Interferon beta adenoviral gene therapy in a patient with ovarian cancer
    Daniel H Sterman
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA
    Nat Clin Pract Oncol 3:633-9. 2006
    ..Diagnosis Stage IV ovarian cancer with malignant ascites and pleural effusion. Management Tunneled pleural catheter and intrapleural adenoviral-mediated interferon beta gene therapy...
  12. ncbi request reprint A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses
    Daniel H Sterman
    Thoracic Oncology Gene Therapy Program and Abramson Family Cancer Research Institute, University of Pennsylvania Medical Center, Philadelphia, PA 19104 4283, USA
    Clin Cancer Res 13:4456-66. 2007
    ..IFN-beta) in patients with malignant pleural mesothelioma (MPM) and metastatic pleural effusions (MPE)...
  13. pmc Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
    Erica L Carpenter
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Transl Med 7:93. 2009
    ....
  14. ncbi request reprint Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT
    Dih Yih Chen
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 6:1991-6. 2007
    ..Thus, I540-specific T cells can vary in cytotoxic potential depending on the method of generation, isolation and expansion...
  15. pmc A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions
    Daniel H Sterman
    Section of Interventional Pulmonology and Thoracic Oncology, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104 4283, USA
    Mol Ther 18:852-60. 2010
    ..This approach was safe, induced immune responses and disease stability. However, rapid development of Nabs prevented effective gene transfer after the second dose, even with a dose interval as short as 7 days...
  16. ncbi request reprint Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma
    Peter DeLong
    Thoracic Oncology Research Laboratory, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 4:342-6. 2005
    ..These results have implications for the development of immunotherapy directed to the malignant pleural space, and suggest the need to tailor immunotherapy to overcome immunosuppressive mechanisms in tumor environments...
  17. ncbi request reprint Telomerase as a universal tumor-associated antigen for cancer immunotherapy
    Robert H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
    Oncogene 21:674-9. 2002
    ..Given the vast overexpression of hTERT in human tumors and its low-level expression in rare normal tissues, clinical trials have begun that test the credentials of hTERT as a broadly applicable target for immunotherapy of cancer...
  18. ncbi request reprint Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients
    Gwenn Aël H Danet-Desnoyers
    Division of Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Exp Hematol 33:1275-80. 2005
    ....
  19. ncbi request reprint Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance
    Susan M Domchek
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cancer Res 67:10546-55. 2007
    ..These results suggest that hTERT-specific T cells could contribute to the immunosurveillance of breast cancer and suggest novel opportunities for both therapeutic and prophylactic vaccine strategies for cancer...
  20. pmc Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers
    Erica L Carpenter
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:4277-87. 2009
    ..This study aimed to investigate whether B-cell physiology was altered in the presence of melanoma and other cancers...
  21. doi request reprint Telomerase as a universal tumor antigen for cancer vaccines
    Gregory L Beatty
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRBII III, 421 Curie Boulevard, Philadelphia, PA 19104, USA
    Expert Rev Vaccines 7:881-7. 2008
    ..Findings obtained from these trials will inform the possibility of broad-spectrum cancer immunotherapy or even immunoprevention...
  22. doi request reprint Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells
    Andrew J Rech
    Abramson Family Cancer Research Institute and the University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Ann N Y Acad Sci 1174:99-106. 2009
    ..If confirmed in additional patients, these observations suggest that daclizumab may be an effective and available therapeutic agent for Treg modulation in patients with cancer...
  23. doi request reprint Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells
    Robert H Vonderheide
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 16:3485-94. 2010
    ..Tremelimumab is a fully human monoclonal antibody specific for CTL-associated antigen 4 (CTLA4) with single-agent activity in certain tumors but has not been evaluated in patients with breast cancer...
  24. ncbi request reprint Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes
    Robert H Vonderheide
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 10:828-39. 2004
    ..Moreover, because survival of hTERT+ tumor cells requires functionally active telomerase, hTERT mutation or loss as a means of escape may be incompatible with sustained tumor growth...
  25. doi request reprint Regulatory T cells: overcoming suppression of T-cell immunity
    Tatiana N Golovina
    Abramson Family Cancer Research Institute and the University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cancer J 16:342-7. 2010
    ..More sophisticated techniques that have become available for Treg analysis in patients will assist in this important translational effort...
  26. ncbi request reprint Cancer-testis antigens in tumor biology and immunotherapy
    CAROLYN E CLARK
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Cancer Biol Ther 5:1226-7. 2006
  27. ncbi request reprint Getting to the surface: a link between tumor antigen discovery and natural presentation of peptide-MHC complexes
    CAROLYN E CLARK
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 11:5333-6. 2005
  28. ncbi request reprint Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
    Brian J Czerniecki
    Department of Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Res 67:1842-52. 2007
    ..DC1 vaccination strategies may therefore have potential for both the prevention and the treatment of early breast cancer...
  29. pmc Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction
    Jan C Schmollinger
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:3398-403. 2003
    ..These findings demonstrate that ML-IAP can serve as a target for immune-mediated tumor destruction, but that antigen-loss variants can accomplish immune escape...
  30. pmc Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo
    Gregor S D Reid
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:6602-8. 2009
    ..To investigate the impact of interferon-gamma-mediated upregulation of major histocompatibility complex class I expression on tumor-specific T-cell cytotoxicity and T-cell trafficking into neuroblastoma tumors in vivo...
  31. ncbi request reprint Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display
    Rolf K Swoboda
    Immunology Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Res 67:3555-9. 2007
    ..The RPL8 antigen may represent a relevant vaccine target for patients with melanoma, glioma, and breast carcinoma whose tumors express this protein...
  32. ncbi request reprint Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C
    David E Kaplan
    Gastroenterology Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Gastroenterology 132:654-66. 2007
    ..Although HCV-specific CD4 T-cell response is associated with HCV clearance, less is known about virus-specific CD8 T-cell or neutralizing antibody (nAb) responses and the role of CD4 help in their induction during acute infection...
  33. ncbi request reprint Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
    Ginna G Laport
    Translational Research Program, Abramsonm Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Blvd, Philadelphia, PA 19104 6160, USA
    Blood 102:2004-13. 2003
    ....
  34. ncbi request reprint Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma
    Britta Maecker
    Department of Adult Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA
    Br J Haematol 121:842-8. 2003
    ..Prospective studies will determine whether such immune assessment strategies may identify patients more likely to benefit from cancer immunotherapy...
  35. ncbi request reprint Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration
    Erica L Carpenter
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, United States
    J Neuroimmunol 193:173-82. 2008
    ..In contrast, viral-specific CD8(+) T cells from healthy volunteers and PCD patients were measurable. These findings are inconsistent with an obligate role for cdr2-1- or cdr2-2-specific CD8(+) T cells in the pathogenesis of PCD...
  36. ncbi request reprint HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy
    Antonio Scardino
    Institut National de la Santé et de la Recherche Médicale Unité 487, Institut Gustave Roussy, Villejuif, France
    J Immunol 168:5900-6. 2002
    ..These results suggest that heteroclitic variants of low affinity, cryptic epitopes of widely expressed tumor Ags may serve as valid tools for tumor immunotherapy...
  37. ncbi request reprint The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells
    Britta Maecker
    Head, Molecular Tumor Biology and Tumor Immunology University of Cologne, Joseph Stelzmann Str 9 Haus 16, 50924 Cologne, Germany
    Blood 102:3287-94. 2003
    ..These findings form the basis of a phase 1 clinical trial exploring a DNA-based vector encoding CYP1B1 for widely applicable cancer immunotherapy conducted at the Dana-Farber Cancer Institute...
  38. ncbi request reprint Targeting adult and pediatric cancers via cell-based vaccines and the prospect of activated B lymphocytes as a novel modality
    Christina M Coughlin
    Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania USA
    Cancer Biol Ther 2:466-70. 2003
    ....
  39. pmc High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy
    David Alexandre Gross
    Institut National de la Santé et de la Recherche Médicale Unité 487, Institut Gustave Roussy, Villejuif, France
    J Clin Invest 113:425-33. 2004
    ..Our results strongly argue for new TAA epitope selection and modification strategies in antitumor immunotherapy applications in humans...
  40. ncbi request reprint Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation
    Daniel H Fowler
    Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 12:1150-60. 2006
    ..Allograft augmentation with costimulated, IL-4-polarized donor CD4(+) T cells resulted in activated Th1, Th2, and inflammatory cytokine pathways without an apparent increase in GVHD...

Research Grants6

  1. TELOMERASE AS A WIDELY EXPRESSED TUMOR ANTIGEN
    Robert Vonderheide; Fiscal Year: 2004
    ..Lee M. Nadler, a recognized leader in the field of tumor immunology with a strong track record for fostering the career development of physician-scientists. ..
  2. Immunoregulation and immunotherapy of breast cancer
    Robert Vonderheide; Fiscal Year: 2005
    ..This trial will determine the effect of daclizumab on the disruption of Treg function and the effect of daclizumab on the immunogenicity of vaccine as well as clinical response of patients with breast cancer. ..
  3. Immunoregulation and immunotherapy of breast cancer
    Robert Vonderheide; Fiscal Year: 2006
    ..This trial will determine the effect of daclizumab on the disruption of Treg function and the effect of daclizumab on the immunogenicity of vaccine as well as clinical response of patients with breast cancer. ..
  4. Immunoregulation and immunotherapy of breast cancer
    Robert Vonderheide; Fiscal Year: 2007
    ..This trial will determine the effect of daclizumab on the disruption of Treg function and the effect of daclizumab on the immunogenicity of vaccine as well as clinical response of patients with breast cancer. ..
  5. Immunoregulation and immunotherapy of breast cancer
    Robert Vonderheide; Fiscal Year: 2009
    ..The long-term goal is to develop an immune-based therapy that offers clinical benefit to patients with hormone receptor positive breast cancer. ..
  6. Immunoregulation and immunotherapy of breast cancer
    Robert H Vonderheide; Fiscal Year: 2010
    ..The long-term goal is to develop an immune-based therapy that offers clinical benefit to patients with hormone receptor positive breast cancer. ..